RxDoctor Payments Data

David Clifford, MD

Family Medicine · West Seneca, NYNPI 1386604775

Payments from drug & device makers

$8,449in general payments, 2019–2025

Across 427 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$739
  • AbbVie$546
  • Pfizer$477
  • GSK$410
  • Amarin Pharma, Inc.$385
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,11196%
  • Education$3394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,449 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$14,267
Medicare patients
38
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$113,005
JardianceEmpagliflozin51$68,968
OzempicSemaglutide37$45,525
TrulicityDulaglutide30$29,998
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$25,705
TrintellixVortioxetine Hydrobromide30$23,656
XareltoRivaroxaban15$21,035
Icosapent Ethyl40$19,274
FarxigaDapagliflozin Propanediol22$18,461
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$13,588
Rosuvastatin Calcium573$11,268
VascepaIcosapent Ethyl17$8,734
Levothyroxine Sodium331$6,528
MyrbetriqMirabegron12$6,237
Metoprolol Succinate176$5,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Levoxyl$477$115,590141 claims
Boehringer IngelheimJardiance$142$68,96851 claims
Novo NordiskOzempic$739$45,52537 claims
GSKTrelegy Ellipta, Anoro Ellipta$410$39,29347 claims
Lilly USA, LLCTrulicity$272$29,99830 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$193$23,65630 claims
Johnson & JohnsonXarelto$206$21,03515 claims
AstraZenecaFarxiga$2,185$18,46122 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$43$6,528331 claims
Astellas Pharma US IncMyrbetriq$337$6,23712 claims
AbbVieSynthroid$546$2,04530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in West Seneca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →